Cardio Diagnostics (NASDAQ:CDIO) Given New $1.35 Price Target at Benchmark

Cardio Diagnostics (NASDAQ:CDIO) had its price objective cut by Benchmark from $4.00 to $1.35 in a report released on Friday morning, Benzinga reports. They currently have a speculative buy rating on the stock.

Cardio Diagnostics Trading Down 20.2 %

Shares of NASDAQ CDIO opened at $0.87 on Friday. The stock has a 50 day simple moving average of $1.41 and a 200-day simple moving average of $1.51. Cardio Diagnostics has a 12-month low of $0.17 and a 12-month high of $3.56.

Institutional Investors Weigh In On Cardio Diagnostics

A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Cardio Diagnostics by 262.6% in the fourth quarter. Vanguard Group Inc. now owns 232,139 shares of the company’s stock worth $578,000 after purchasing an additional 168,117 shares during the period. Northern Trust Corp acquired a new stake in shares of Cardio Diagnostics during the 4th quarter valued at $115,000. Vontobel Holding Ltd. acquired a new stake in shares of Cardio Diagnostics during the 4th quarter valued at $30,000. State Street Corp acquired a new stake in shares of Cardio Diagnostics during the 1st quarter valued at $163,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Cardio Diagnostics during the 1st quarter valued at $290,000. 8.06% of the stock is currently owned by institutional investors and hedge funds.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc, an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.